Welcome to our dedicated page for Capstone Holding SEC filings (Ticker: CAPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Capstone Holding Corp. filings document the regulatory record for a Nasdaq-listed emerging growth company operating a tech-enabled building products distribution platform. Its reports cover common stock listing details, convertible-note financing, working-capital and capital-structure disclosures, Regulation FD updates tied to investor FAQs and operating outlooks, and amendments to material-event reports.
Proxy and current-report filings address director elections, auditor ratification, a proposed reverse stock split authorization, related-party fee waiver and deferral arrangements, acquisition activity involving operating subsidiaries such as TotalStone and InStone Canada, delayed annual-report notice, and Nasdaq continued-listing matters.
TOPOREK MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Capstone Holding Corp. director Michael Toporek reported an amended grant of 356,250 shares of common stock as restricted stock awards on March 30, 2026, issued for no consideration. These shares vest only upon specified Board-related events, bringing his reported direct holdings to 391,678 shares, excluding 121,774 shares controlled through BP Peptides, LLC.
Capstone Holding Corp. director Michael Toporek purchased 41,750 shares of Common Stock on March 7, 2025 at $4.00 per share in a purchase in open market or private transaction. After this transaction, he directly holds 41,750 Capstone Holding Corp. Common Stock shares.
Capstone Holding Corp. director Michael Toporek reports his initial beneficial ownership, consisting entirely of indirect holdings. As of February 14, 2025, he controls 121,774 shares of Common Stock through BP Peptides, LLC and related entities, and an indirect warrant to purchase up to 6,322 shares of Common Stock at an exercise price of $75.00 per share, expiring on October 15, 2028. The warrant is held by Brookstone Partners IAC, Inc., investment manager to BP Peptides, LLC, which is controlled by Matthew Lipman and Michael Toporek.
Capstone Holding Corp. filed an initial insider report identifying Elwood D. Howse as a director of the company. This Form 3 submission lists no buy or sell transactions, no derivative transactions, and no specific holdings or derivative positions for him in this report.
Capstone Holding Corp. reports that Strout Gordon Lewis Jr is a reporting person in his capacity as a director through an initial Form 3 statement of beneficial ownership. The filing records no purchases, sales, derivative transactions, or holding entries in the company’s securities for him at this time.
Capstone Holding Corp. director and Chief Executive Officer Matthew E. Lipman reported purchasing 41,750 shares of Common Stock at $4.00 per share on March 7, 2025, increasing his direct holdings to 2,570,412 shares. The transaction is not designated under a Rule 10b5-1 trading plan.
Lipman Matthew E. reported acquisition or exercise transactions in this Form 4 filing.
Capstone Holding Corp. amended a prior insider report to clarify that Chief Executive Officer Matthew E. Lipman received a grant of 356,250 shares of common stock as restricted stock awards on March 30, 2026, vesting in full on March 30, 2029, for no consideration.
After this grant, he directly holds 2,920,340 shares of common stock. This figure excludes an additional 121,774 shares he controls through BP Peptides, LLC.
SCHULTZ EDWARD CHRISTOPHER reported acquisition or exercise transactions in this Form 4 filing.
An insider disclosure for Capstone Holding Corp. states that Chief Financial Officer Edward Christopher Schultz received a grant of 190,000 shares of common stock on March 30, 2026 as restricted stock awards, for no consideration. These shares vest in full on March 30, 2029, subject to his continued service. The Form 4/A amendment corrects an earlier description, clarifying that the grant consists of common shares rather than restricted stock units.
Capstone Holding Corp. officer Kevin Allan Grotke reported beneficial ownership of 526,102 shares of common stock held directly. This amount includes 285,000 shares granted to him on March 30, 2026 as restricted stock awards for no consideration, vesting in full on March 30, 2029, subject to his continued service.